PRELUDE THERAPEUTICS INC (PRLD) Stock News
NASDAQ:PRLD - Nasdaq - US74065P1012 - Common Stock - Currency: USD
PRLD Latest News, Press Relases and Analysis
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
WILMINGTON, Del., June 02, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology...
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
PRT3789 monotherapy and combination with docetaxel escalation enrollment is complete and the Company plans to present updated results in the second half of...
Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Prelude Therapeutics to Participate in Citizens Life Sciences Conference
WILMINGTON, Del., May 01, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology...
Prelude Therapeutics to Participate in Citizens Life Sciences Conference
Prelude Announces Presentations at 2025 AACR Annual Meeting
Preclinical data elucidating the mechanism of action of PRT3789, Prelude’s first-in-class, highly selective SMARCA2 degrader currently in early clinical...
Prelude Announces Presentations at 2025 AACR Annual Meeting
Gossamer Bio, Inc. (GOSS): Among Stocks Under $10 that Will Triple
We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where Gossamer Bio, Inc. (NASDAQ:GOSS) stands against other stocks under $10 that will triple. As we delve into the discussion on stocks that will triple, we must shed light on the […]
Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025
PRT3789 has demonstrated clinical proof-of-concept that selectively degrading SMARCA2 is generally safe and has monotherapy anti-tumor activity in patients...
Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025
Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference
WILMINGTON, Del., March 05, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology...
Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
• PRT2527 demonstrated activity across a range of relapsed/refractory lymphoid malignancies, including patients who received prior CAR-T therapy •...
Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit
WILMINGTON, Del., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology...
Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit
Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium
– Interim data from ongoing trial of PRT3789 showed additional clinical activity at higher doses in patients with non-small cell lung cancer (NSCLC) –...
Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium
PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation plenary session presentation: October...
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium
PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation plenary session presentation: October 24, 2024, 10:00 AM CEST (4:00 AM EST)
Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
- Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and...
Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024
PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation oral session presentation: September 13,...